NAD+ Boosters and Drips

NAD+ (nicotinamide adenine dinucleotide) is genuinely central to biology — the redox coenzyme of energy metabolism and the substrate of sirtuins and PARPs, declining with age in many tissues, restored in old mice with precursor feeding to headline-generating effect. On that real foundation stands one of wellness's most confident markets: oral precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — at $30-150 monthly, and the clinic tier: intravenous NAD+ drips at $200-1,000 per multi-hour session, sold for energy, longevity, brain fog, addiction recovery and hangovers. The market's core rhetorical move is a two-step this collection recognises from every longevity aisle: cite the mouse data and the mechanism (real), cite human studies showing blood NAD rises with supplementation (also real), and let the customer complete the syllogism to health benefits — the step where, as the next message details, the actual human trials keep declining to cooperate.

The precursor science has now been tested properly, and the pattern is consistent: oral NR and NMN reliably raise blood NAD metabolites (pharmacology confirmed), are well tolerated at studied doses (safety reasonable short-term), and — across randomised trials in overweight and older adults measuring insulin sensitivity, mitochondrial function, blood pressure, physical performance, and metabolic endpoints — deliver little to nothing clinically: the flagship NR trials in obesity and prediabetes came back null on their metabolic primary endpoints, NMN trials report scattered small findings (a muscle insulin-sensitivity signal in one prediabetic-women study, modest walking-distance changes elsewhere) that don't replicate into a coherent benefit, and no trial anywhere has measured the outcomes the marketing sells — ageing, lifespan, sustained energy, cognition in healthy people. The honest scientific position, held by most NAD researchers themselves: an interesting biology with translation unproven, possibly dose- or tissue-limited, worth continued trials — a status the $500-million market renders in rather different typography. Boring footnote with teeth: plain nicotinamide and nicotinic acid — pennies-cheap B3 forms — also feed NAD synthesis, a fact the premium-precursor economy structurally cannot mention.

The drip lounges occupy this hub's bottom evidentiary floor. What exists: no controlled trials of IV NAD+ for any marketed indication — energy, longevity, cognition, “cellular repair” — none; the addiction-recovery corner (NAD drips for withdrawal, a decades-old fringe protocol) runs on case series and clinic testimony without a single adequate randomised trial; and the acute pharmacology argues against the premise anyway (infused NAD+ is largely degraded extracellularly; cells synthesise their own from precursors — the expensive molecule mostly doesn't enter as itself). What is documented: the infusion-reaction profile — chest pressure, nausea, cramping and flushing when run fast, the rate-dependent discomfort that clinics manage by slowing the drip and reframe as “feeling it work” — plus the standing IV-clinic file this collection maintains: cannulation risks, sterility dependence, and zero regulation of the compounded product in the bag. The economics complete the picture: the same precursor chemistry sold orally for a dollar a day retails intravenously at $500 an afternoon, with the needle supplying the pharmacological theatre the outcome data cannot.

NAD's market has its own regulatory drama worth reading correctly. In 2022 the US FDA concluded NMN is excluded from the dietary-supplement definition — because it had been authorised for investigation as a new drug first (the exclusion provision protecting drug development) — throwing the ingredient's US retail status into limbo: industry petitions, congressional letters, continued de-facto sales under enforcement discretion, and offshore rebranding followed, while NR (which navigated the pathway earlier with NDI notifications and GRAS status) kept its lane. The episode is a clean specimen of the supplements-industry hub's central theme: the US framework's drug/supplement boundary is procedural rather than evidential — the same molecule can be a supplement, an excluded article or an investigational drug depending on filing order, with consumer-facing certainty unmoved throughout. For buyers the practical residue: NMN products in some markets are quasi-grey imports of variable provenance; third-party-tested NR or plain B3 forms have cleaner supply chains; and no version of the paperwork resolves the actual question, which remains the trial record above.

NAD is the type specimen of the modern longevity content economy. The pipeline: a charismatic-scientist tier (sirtuin researchers whose labs, companies and books intertwined — with the resveratrol prequel as the cautionary memory: the same ecosystem's previous molecule, GSK's half-billion-dollar buyout, and the subsequent scientific deflation), a podcast layer converting preprints into protocols, a supplement industry timing launches to episodes, and a retesting loop (biological-age tests, the adjacent hub) selling the measurement of the improvement the first product promised. The critical-thinking toolkit it trains: distinguish biomarker movement from outcome benefit (blood NAD is to health here what LDL would be if statins had never been outcome-tested); note conflict density (when the paper's author sells the molecule, read twice); watch for the boring-comparator omission (nicotinamide, exercise — which raises muscle NAD synthesis machinery — and sleep never headline); and price hope per gram: the premium between NMN and plain B3 is almost entirely narrative. None of this convicts the biology — NAD research is real and continuing; it convicts the certainty being retailed a decade ahead of it.

Skip the drips entirely: no controlled evidence supports IV NAD+ for anything it is sold for, the infused molecule mostly doesn't enter cells as itself, the documented effects are infusion reactions, and the price buys theatre — the addiction-recovery version included, where vulnerable buyers deserve actual evidence-based treatment. On oral precursors: safe at studied doses and pharmacologically active but clinically unproven — if you enjoy the experiment, use third-party-tested products, know that trials keep coming back null on outcomes, and consider that plain nicotinamide feeds the same pathway at a fraction of the cost; if you want the money to buy ageing outcomes, the interventions with actual human evidence remain the unsellable stack (exercise — which upregulates NAD synthesis machinery — sleep, diet pattern, blood pressure, not smoking). Watch the space honestly: NAD biology is a live research field and a future trial could change this page — the signal will be outcome trials in journals, not a launch timed to a podcast. And the transferable rule: when levels rise and outcomes don't, you have bought a biomarker — this market's entire product line is the space between those two curves.